Artera.ai is an artificial intelligence company that specializes in providing advanced AI-driven solutions for various industries. Their offerings may include machine learning algorithms, data analytics services, and AI-powered software tools designed to enhance business operations, decision-making processes, and customer experiences.

Joe Tischler

Guillaume De Zwirek

Artera.ai

Deciphex provides digital pathology solutions that leverage AI to enhance pathology service delivery and improve diagnostic turnaround times.

Donal O'Shea

Mark Gregson

Mairin Rafferty

Deciphex

Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer.

Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.

ArteraAI

How will #AI decrease overtreatment of #prostatecancer?

ArteraAI's Tim Showalter, Chief Medical Officer, will join Daniel Spratt, MD, Chair of radiation #oncology at University Hospitals in Cleveland; Niels Olson, MD, board-certified pathologist and the Chief Medical Officer at the Defense Innovation Unit (DIU) in Mountain View, California; and Bruno Barrey, a robotics engineer from suburban Detroit, who was able to avoid Androgen Deprivation Therapy with the help of the ArteraAI Prostate Test as he transitioned from Active Surveillance to radiation treatment - in the Active Surveillance Patients International (ASPI) panel on Feb. 24 at noon ET.

➡️ Register today:

Get to know #ArteraAI's Michiel deRoos, Senior Software Engineer - February's Employee of the Month! 👏 

Here's what his peers had to say about his work at ArteraAI:

"Michiel has been an extremely essential part of activities that are vital to our company's success."

Congratulations, Michiel! We're proud to have you on our team. 

#personalizedcancercare #prostatecancer #AI #precisionmedicine

How is AI helping meet patient expectations in health care?

Fox News Media explores how tools like #artificialintelligence and #machinelearning mean that patients no longer need to be treated "as generic cases with uniform treatment regimens, but rather as individuals with distinct care needs and desires."

At ArteraAI, our multimodal AI #prostatetest provides individualized results, enabling personalized treatment decision-making between clinicians, and patients with localized #prostatecancer.

Today’s standard of care for men with localized, intermediate-risk #prostatecancer is treatment with short-term androgen-deprivation therapy in combination with radiation therapy, but only 34% actually need it - and side effects can mean medical castration.

The ArteraAI #ProstateTest is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. 

By assessing digital images from a patient’s biopsy and learning from a patient’s clinical data, our unique algorithm identifies the 34% of patients who may greatly benefit from short-term hormone therapy. Test results are generated without consuming tissue and are available to review within 2-3 days after receipt of the patient's specimen.

➡️ View a sample test report and see how it can help personalize prostate cancer treatment: https://lnkd.in/e58v3HbW

Cancer is personal. Cancer therapy should be, too.

When Pat was diagnosed with #prostatecancer in 2022, it came with multiple stressors.

After being seen for a routine physical that was delayed due to the pandemic, his PSA levels were high, prompting his physician to recommend seeing a urologist and having a biopsy. He would soon find out that his physician passed away (stress #1), and was introduced to a new team that recommended surgery (stress #2). Then, followed radiation therapy (stress #3). With little information on the appropriate timing, and reports that spoke in medical jargon, Pat struggled to understand the information before him, eventually going through radiation therapy and short term hormonal therapy.

Pat would later discover the #ArteraAI Prostate Test:
"If I had this data available to me, it would have been a lot less stress on myself, my family, and my support team."

The first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer, The ArteraAI #ProstateTest leverages a unique algorithm, assesses digital images from a patient’s biopsy, and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from hormone therapy and estimate long-term outcomes.

Cancer is personal. Cancer therapy should be, too. Learn more at artera.ai.

There are substantial disparities affecting people from racial and ethnic minority groups with higher rates of cancer. 

One in six Black men will develop #prostatecancer in their lifetime, according to ZERO Prostate Cancer, while research from the American Cancer Society shows Black men are more than twice as likely to die from the disease than their White counterparts.

While early action, like screening and detection, is encouraged - it's important to note that not all prostate cancers are the same, underscoring the need to understand a patient's individual risk for outcomes such as metastasis or prostate cancer-specific mortality. Standard #prognostic tools can rely on non-specific and semi-quantitative measures, which may lead to over/under-treatment. 

#ArteraAI #biomarker tests - developed using datasets comprised of about 20% African Americans - can predict therapeutic benefit and estimate long-term outcomes to support personalized treatment decision-making.

ICYMI: ArteraAI recently announced the securement of an additional $20 million in capital fueled by several prominent large investment funds to ensure broader accessibility to #AI-enabled personalized care.

“The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and #prognostic tests,” said Andre Esteva, PhD, CEO and Co-Founder of ArteraAI. 

“We are committed to ushering in the era of #precisionmedicine, and stewarding this investment strategically to aid in our international expansion and commercial growth.”

➡️ Read the full announcement from HIT Consultant Media:

Like many cancers, there is no sure way to prevent #prostatecancer. 

Many #prostate cancer risk factors, such as age, race, and family history, can’t be controlled. But there are some things you can do that might lower your risk. From diet and activity to supplements and more, The American Cancer Society (ACS) shares the latest research in preventative measures: https://bit.ly/3UqPncq 

#NationalCancerPreventionMonth #NCPM

Our team had a great time meeting attendees and discussing how the ArteraAI Prostate Test can predict the therapeutic benefit from adding hormone therapy to radiation therapy in patients with localized, intermediate-risk #prostatecancer. ➡️ Learn more at artera.ai. 

#ASCOGU #ArteraOnTheGo

ArteraAI is thrilled to announce that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI Pte Ltd, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC).

The announcement follows closely on the heels of #ArteraAI's recent achievement of the Centers for Medicare & Medicaid Services (CMS) decision on the payment rate for the ArteraAI #ProstateTest. The decision helps to ensure broader accessibility to #AI-enabled #personalizedcare, benefiting a larger population.
 
➡️ Read the full announcement from Axios:

Metric
Company Name	Artera.ai	Deciphex
Symbol
MSH ID	AI:ARTERA	COM:DECIPHEX
Market	PRIVATE	PRIVATE
Sector	Technology	Healthcare & Health Services
Industry	Artificial Intelligence & Machine Learning	Medical Technology
Country	US	IE
Stage		Debt Financing
Employee Count	94	118
Website	artera.ai	deciphex.com
LinkedIn	arteraai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		1.24K
Web Traffic Growth		-0.17
Valuation
Raised Capital		10.55M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AI:ARTERA

Artera.ai

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue